Context Therapeutics IncNASDAQ:CNTX
- LAST PRICE1.4100
- TODAY'S CHANGE (%)0.0200 (1.4388%)
- Bid / Lots1.3000/ 20
- Ask / Lots1.4300/ 6
- Open / Previous Close1.4400 / 1.3900
- Day Range
- 52 Week Range
- Volume45,923
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNTX |
|---|---|---|
| 09:45 ET | 200 | 1.44 |
| 10:03 ET | 3053 | 1.43 |
| 10:44 ET | 1285 | 1.3901 |
| 10:53 ET | 800 | 1.42 |
| 10:55 ET | 1000 | 1.44 |
| 10:57 ET | 1300 | 1.5 |
| 11:09 ET | 251 | 1.3954 |
| 11:13 ET | 300 | 1.45 |
| 11:24 ET | 500 | 1.4182 |
| 11:40 ET | 100 | 1.43 |
| 12:27 ET | 100 | 1.4 |
| 12:30 ET | 15010 | 1.4 |
| 12:32 ET | 200 | 1.45 |
| 12:34 ET | 300 | 1.46 |
| 12:36 ET | 12377 | 1.45 |
| 12:38 ET | 2468 | 1.46 |
| 01:48 ET | 450 | 1.45 |
| 02:54 ET | 100 | 1.4283 |
| 03:09 ET | 355 | 1.42 |
| 03:27 ET | 1243 | 1.42 |
| 03:36 ET | 100 | 1.43 |
| 03:41 ET | 2099 | 1.379 |
| 03:45 ET | 200 | 1.41 |
| 03:57 ET | 100 | 1.37 |
| 03:59 ET | 250 | 1.41 |
Apr 1, 2024
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers, from 7:30AM ET on Monday Apr 01, 2024 by Dow Jones
7:30AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 21, 2024
DJ Context Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 12:31PM ET on Thursday Mar 21, 2024 by Dow Jones
12:31PM ET on Thursday Mar 21, 2024 by Dow JonesContext Therapeutics Reports Full Year 2023 Operating and Financial Results, from 7:43AM ET on Thursday Mar 21, 2024 by Dow Jones
7:43AM ET on Thursday Mar 21, 2024 by Dow JonesPress Release: Context Therapeutics Reports Full Year 2023 Operating and Financial Results, from 7:43AM ET on Thursday Mar 21, 2024 by Dow Jones
7:43AM ET on Thursday Mar 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Context Therapeutics Inc | 22.2M | -0.9x | --- |
Cardio Diagnostics Holdings Inc | 22.0M | -1.5x | --- |
Indaptus Therapeutics Inc | 22.7M | -1.4x | --- |
Biora Therapeutics Inc | 21.4M | -0.1x | --- |
Lisata Therapeutics Inc | 23.1M | -1.1x | --- |
Bullfrog AI Holdings, Inc. | 22.9M | -3.3x | --- |
Company Information
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, which is in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window, which is the difference between the dose required for the intended therapeutic effect and the dose required to elicit an unwanted side effect.
Contact Information
- Headquarters
- 2001 Market Street, Suite 3915 Unit #15PHILADELPHIA, PA, United States 19103
- Phone
- 267-225-7416
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Berman
- President, Chief Executive Officer, Director
- Martin Lehr
- Chief Financial Officer, Treasurer
- Jennifer Minai-Azary
- Senior Vice President - Operations
- Christopher Beck
- Vice President - Clinical Operations
- Priya Marreddy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.50 |
Book Value | $0.74 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
